Ayurvedic treatment of kidney stone

A Clinical Evaluation Of Shikhiadi Compound in Mutrashmari urolithiasis - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/06/112041

Enrollment

Registered

2026-06-05

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N20-N23- Urolithiasis

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patient willing to sign the consent form. 2.Patients having features of Mutrashmari according to Ayurvedic and modern texts, will be selected irrespective of gender , religion , occupation , and socio- economic status. 3.Patients with stones size less than 1.5 cms. in diameter in anypart of urinary system.

Exclusion criteria

Exclusion criteria: 1.Patient with k/c/o TB, HIV, HCV ,Hbsag, VDRL. 2.Patients with obstruction in urinary passage and with immediate surgical requirement had been excluded from the study. 3.Associated with uncontrolled Diabetes Mellitus and Hypertension. 4.Patient suffering from systemic infectious disease. 5.Patients undergoing treatment for any other serious illness. 6.Patients who were not willing for trial. 7.Patients who fail to give consent. 8.H/O of hypersensitivity of any trail drug. 9.Patients suffering from - Chronic kidney Disease, Pyelonephritis, Nephrotic Syndrome, Diabetic Nephropathy, Poorly Functioning Kidney,Malignancy.

Design outcomes

Primary

Measure	Time frame
Assessment of the overall clinical efficacy of Shikhiadi Compound in the management of Mutrashmari (Urolithiasis). This is determined by measuring the relief in subjective symptoms (Shoola/Pain, Mutradaha/Burning micturition, and Mutrakrichhata/Dysuria) and improvement in objective parameters (reduction in stone size and number assessed via USG K.U.B., as well as the reduction of RBCs, pus cells, and crystals via routine urine microscopic examination) using a standardized clinical grading scale.Timepoint: Baseline (Day 0), Day 30, Day 60, Day 90 (End of Treatment), Day 105 (1st Follow-up), Day 120 (2nd Follow-up), and Day 135 (3rd Follow-up).	—

Measure

Time frame

Assessment of the overall clinical efficacy of Shikhiadi Compound in the management of Mutrashmari (Urolithiasis). This is determined by measuring the relief in subjective symptoms (Shoola/Pain, Mutradaha/Burning micturition, and Mutrakrichhata/Dysuria) and improvement in objective parameters (reduction in stone size and number assessed via USG K.U.B., as well as the reduction of RBCs, pus cells, and crystals via routine urine microscopic examination) using a standardized clinical grading scale.Timepoint: Baseline (Day 0), Day 30, Day 60, Day 90 (End of Treatment), Day 105 (1st Follow-up), Day 120 (2nd Follow-up), and Day 135 (3rd Follow-up).

—

Secondary

Measure	Time frame
To assess the safety and tolerability of Shikhiadi Compound by monitoring for any Adverse Drug Reactions (ADRs) and evaluating changes in routine hematological and biochemical parameters (such as CBC, Blood Urea, and Kidney Function Tests).Timepoint: Baseline (Day 0) and End of Treatment (Day 90).	—

Countries

India

Contacts

Public ContactDr Bhoomi Soni

Quadra institute of ayurveda

bhoomi629@gmail.com9008637659

Outcome results